Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   ARCHIVES OF ADVANCES IN BIOSCIENCES (JOURNAL OF PARAMEDICAL SCIENCES)   SPRING 2016 , Volume 7 , Number 2; Page(s) 1 To 7.
 
Paper: 

ANTI –MBP AUTOANTIBODY CHANGES AS A PREDICTOR OF RESPONSE TO TREATMENT IN MS PATIENTS

 
 
Author(s):  GHOLINEJAD KHADIJEH, RAHIMIPOUR ALI*, SAHRAIAN MOHAMMAD ALI, NAMAKI SAEED, KAZEROUNI FARANAK, NASER MOGHADASI ABDORREZA, RAHIMI FOROUGH, BOROUMANDNIA NASRIN
 
* DEPARTMENT OF MEDICAL LAB TECHNOLOGY, SCHOOL OF ALLIED MEDICAL SCIENCES, SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES , TEHRAN, IRAN
 
Abstract: 

Myelin basic protein (MBP) is one of the most important constituents of the CNS myelin sheaths. It is supposed that an autoimmune response directed against MBP is crucial in the demyelination process in patients with multiple sclerosis. Studies have proved that free anti-MBP level in CSF of MS patients is declined when the patient entered into clinical remission. Some researchers evaluate the changes in serum or CSF level of this antibody during immunomodulatory therapy; the results are different and the relation between the changes in this antibody and response to treatment is poorly investigated. The objective of this study was to assess the relation between the changes in serum level of anti-MBP and clinical remission in patients during treatment with fingolimod.37 MS patients that were non responder to interferon and glatiramer acetate and were candidates to receive fingolimod were nominated for this study. In this study, the serum level of anti-MBP was evaluated before and after 3 and 6 months of therapy and clinical remission was assessed by changes in Expanded Disability Status Scale (EDSS) scores. The result of this study showed that MS patients, after treatment with interferon, have lower serum anti-MBP level than healthy control group and this difference is statistically significant (p=0.03). The present study demonstrated that the serum anti-MBP level in MS patient during 6 months of treatment with fingolimod significantly decreased (p<0.001). However, there was no significant difference in EDSS of MS patients during 6 months of treatment with fingolimod (p<0.001).

 
Keyword(s): MULTIPLE SCLEROSIS (MS), ANTI-MBP, FINGOLIMOD
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

GHOLINEJAD, K., & RAHIMIPOUR, A., & SAHRAIAN, M., & NAMAKI, S., & KAZEROUNI, F., & NASER MOGHADASI, A., & RAHIMI, F., & BOROUMANDNIA, N. (2016). ANTI –MBP AUTOANTIBODY CHANGES AS A PREDICTOR OF RESPONSE TO TREATMENT IN MS PATIENTS. ARCHIVES OF ADVANCES IN BIOSCIENCES (JOURNAL OF PARAMEDICAL SCIENCES), 7(2), 1-7. https://www.sid.ir/en/journal/ViewPaper.aspx?id=510896



Vancouver: Copy

GHOLINEJAD KHADIJEH, RAHIMIPOUR ALI, SAHRAIAN MOHAMMAD ALI, NAMAKI SAEED, KAZEROUNI FARANAK, NASER MOGHADASI ABDORREZA, RAHIMI FOROUGH, BOROUMANDNIA NASRIN. ANTI –MBP AUTOANTIBODY CHANGES AS A PREDICTOR OF RESPONSE TO TREATMENT IN MS PATIENTS. ARCHIVES OF ADVANCES IN BIOSCIENCES (JOURNAL OF PARAMEDICAL SCIENCES). 2016 [cited 2021August03];7(2):1-7. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510896



IEEE: Copy

GHOLINEJAD, K., RAHIMIPOUR, A., SAHRAIAN, M., NAMAKI, S., KAZEROUNI, F., NASER MOGHADASI, A., RAHIMI, F., BOROUMANDNIA, N., 2016. ANTI –MBP AUTOANTIBODY CHANGES AS A PREDICTOR OF RESPONSE TO TREATMENT IN MS PATIENTS. ARCHIVES OF ADVANCES IN BIOSCIENCES (JOURNAL OF PARAMEDICAL SCIENCES), [online] 7(2), pp.1-7. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=510896.



 
  pdf-File
Yearly Visit 63
 
 
Latest on Blog
Enter SID Blog